Cholesterol Education Program Adult Treatment Research Articles

Evaluation of some biochemical changes and associated metabolic syndrome among pregnant women in Enugu Southeast of Nigeria

Objective: Metabolic syndrome is a global health problem which involves a cluster of conditions that increases the risk of heart disease, stroke and diabetes. Pregnancy induces significant physiological, hormonal and metabolic changes in a woman. The complex of metabolic and hormonal disorders is a risk factor for clinical manifestations of cardiovascular diseases, nephropathy and retinopathy. This study assessed some biochemical changes and associated metabolic syndrome among pregnant women in Enugu, Nigeria. Methods: A total of one hundred and thirty apparently healthy women consisting of seventy pregnant women as test group and sixty non-pregnant women as control group were recruited for this cross sectional study. Anthropometric parameters waist circumference (WC), height, weight, systolic blood pressure (SBP), diastolic blood pressure (DBP) were measured and body mass index (BMI) calculated. Five milliliters of fasting blood samples were collected and used for the determination of fasting plasma glucose (FPG) and lipid profile (TC, TG, HDL-C, LDL-C, VLDL-C) using enzymatic colorimetric methods. Metabolic Syndrome (MetS) prevalence was estimated using the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) and International Diabetes Federation (IDF) criteria. Data was analysed using the Statistical Package for the Social Sciences (SPSS) version 26. Results: The results showed a significant (P< 0.05) increase in BMI, WC, SBP, DBP, TG, VLDL-C and a decrease in HDL-C of pregnant women compared to non-pregnant women. Using the NCEP-ATP III criteria, it was found that about twenty-eight (40%) pregnant women had metabolic syndrome and only two (3.33%) non-pregnant woman had metabolic syndrome while the IDF criteria, presented about thirty (42.9%) pregnant women and ten (16.7%) non-pregnant women with metabolic syndrome. Conclusion: This study concludes that pregnancy predisposes women to higher risk of developing metabolic syndrome.

Metabolic syndrome prevalence in Mexican individuals exposed to polycyclic aromatic hydrocarbons and their association with an increased risk of cardiovascular events

Polycyclic aromatic hydrocarbons (PAHs) are an organic chemical family produced during incomplete combustion of organic materials. Besides, PAHs are associated with different detrimental health effects. Therefore, this research was aimed to assess the association between PAHs exposure, metabolic syndrome (MetS) prevalence, and cardiovascular risk in a Mexican population. Urinary 1-hydroxypyrene (1-OHP) was the exposure biomarker quantified. MetS prevalence was defined using the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) and the International Diabetes Federation (IDF) criteria. Also, we used the atherogenic index of plasma (AIP) as a cardiovascular risk biomarker. The mean urinary 1-OHP level quantified was 2.50 ± 1.25 µmol/mol creatinine. The MetS prevalence found was 35% (n = 222) and 31% (n = 197) using NCEP ATP III and IDF criteria, respectively. The mean AIP value was 0.32 ± 0.15. Furthermore, the data analysis showed robust associations between PAH exposure (urinary 1-OHP concentrations), MetS prevalence, and cardiovascular risk (AIP). The real significance of the findings in this study needs to be clarified completely, as MetS and cardiovascular diseases represent a critical challenge in contaminated zones of developing countries such as Mexico.

Associations of Combined Physical Activity and Body Mass Index with Metabolic Syndrome in American Adults: From the National Health and Nutrition Examination Survey, 2017-2020.

The purpose of this study is to examine the combined associations of physical activity and body mass index with the prevalence of metabolic syndrome in a population-based sample of American adults. Cross-sectional study. Data from the 2017-2020 National Health and Nutrition Examination Survey (NHANES). A total of 2945 American adults who participated in the NHANES 2017-2020. Participants' physical activity levels were categorized based on the Physical Activity Guidelines for Americans. Metabolic syndrome was determined using the National Cholesterol Education Program Adult Treatment Panel III guidelines. The prevalence of metabolic syndrome among the various groups was analyzed using binary logistic regression to observe differences in the associated risks of developing metabolic syndrome. An increase in body mass index and a decrease in physical activity are both risk factors for metabolic syndrome. Statistical results show that the prevalence of metabolic syndrome in the obese and sedentary group is 22.31 times higher than that in the normal weight and active group (P = 0.000). A combination of at least 600 MET-minutes of physical activity per week and a lower body mass index is significantly associated with the lowest prevalence of metabolic syndrome.

Metabolic phenotype and risk of obesity-related cancers in the Women's Health Initiative.

Body mass index (BMI) may misclassify obesity-related cancer (ORC) risk, as metabolic dysfunction can occur across BMI levels. We hypothesized that metabolic dysfunction at any BMI increases ORC risk compared to normal BMI without metabolic dysfunction. Postmenopausal women (n=20,593) in the Women's Health Initiative with baseline metabolic dysfunction biomarkers (blood pressure, fasting triglycerides, high-density lipoprotein-cholesterol, fasting glucose, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and high sensitive C-reactive protein (hs-CRP)) were included. Metabolic phenotype (metabolically healthy normal weight (MHNW), metabolically unhealthy normal weight (MUNW), metabolically healthy overweight/obese (MHO), metabolically unhealthy overweight/obese (MUO)) was classified using four definitions of metabolic dysfunction: (1) Wildman criteria, (2) National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III), (3) HOMA-IR, and (4) hs-CRP. Multivariable Cox proportional hazards regression, with death as a competing risk, was used to assess the association between metabolic phenotype and ORC risk. After a median (IQR) follow-up duration of 21 (IQR 15-22) years, 2,367 women developed an ORC. The risk of any ORC was elevated among MUNW (HR 1.12, 95% CI: 0.90-1.39), MHO (HR 1.15, 95% CI: 1.00-1.32), and MUO (HR 1.35, 95% CI: 1.18-1.54) compared with MHNW using Wildman criteria. Results were similar using ATP III criteria, hs-CRP alone, or HOMA-IR alone to define metabolic phenotype. Individuals with overweight or obesity with or without metabolic dysfunction were at higher risk of ORCs compared with metabolically healthy normal weight individuals. The magnitude of risk was greater among those with metabolic dysfunction, although the confidence intervals of each category overlapped.

STUDY OF SERUM URIC ACID LEVELS IN PATIENTS DIAGNOSED WITH METABOLIC SYNDROME IN A HOSPITAL-BASED STUDY IN WEST BENGAL

Objective: The occurrence of hyperuricemia is growing even in developing countries. It has been known to be associated with metabolic syndrome (MetS). MetS is a bunch of numerous metabolic disorders including reduced high-density lipoprotein cholesterol (HDL-C), hypertension, hyperglycemia, abdominal obesity, and raised triglyceride level in serum. Methods: The present work was done in the Department of Biochemistry in combination with Medicine Department, SRIMS and Sanaka Hospital, Durgapur, WB, India. A total of 50 diagnosed MetS patients were selected for further studies and same number (50) of healthy volunteers controls without MetS were selected. Diagnosis of MetS was done according to the National Cholesterol Education Program Adult Treatment Panel-III. Results: In our study, the level of serum uric acid (SUA) is high in MetS patients (7.8 mg/dL) compared to control group (4.6 mg/dL). The compared between two groups was statistically significant (p<0.000). Conclusion: Our study showed that the components of MetS are increased with rise in the concentrations of SUA.

Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis.

We determined if metabolic syndrome, its components, and adipokines (adiponectin, leptin, and fibroblast growth factor-21) were associated with response to advanced therapies among patients with rheumatoid arthritis (RA). This study included participants with RA initiating either tumor necrosis factor inhibitor (TNFi) or non-TNFi biologic therapies from the Comparative Effectiveness Registry to study Therapies for Arthritis and Inflammatory Conditions (CERTAIN) cohort within the CorEvitas registry. Metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III definition. Adipokines were assessed on stored samples from a subsample of responders and nonresponders (n = 200). The primary outcome was the achievement of a change as large as the minimal clinically important difference (MCID) for the Clinical Disease Activity Index (CDAI) at 6 months. Among 2,368 participants, 687 (29%) had metabolic syndrome. Metabolic syndrome was associated with lower odds of achieving CDAI MCID (odds ratio [OR] 0.69, 95% confidence interval [CI] 0.56-0.86, P = 0.001) with a dose-dependent decrease in response rate according to the number of components present. Model fit was superior for metabolic syndrome compared with body mass index. Associations between metabolic syndrome and MCID achievement were similar between patients receiving TNFi (OR 0.65, 95% CI 0.49-0.87, P = 0.003) versus non-TNF therapies (OR 0.76, 95% CI 0.55-1.04, P = 0.08 [P for interaction = 0.49]). Adipokines were not associated with MCID achievement. Metabolic syndrome is associated with lower response rates with the initiation of an advanced therapy in RA, with similar effects for both TNFi and non-TNFi agents. Adipokines were strongly associated with metabolic syndrome but were not associated with clinical response.

The Independent Association Between Changes in Physical Activity Participation Time and Dyslipidemia Risk

Background and AimThis study aimed to examine the independent association between changes in participation time across different types of physical activities and dyslipidemia. Methods and ResultsThe study utilized data from a large-scale cohort survey of Koreans, comprising a total of 2,543 participants recruited during 2011-2012 and 2013-2014. Physical activity participation times by type were assessed using validated questionnaires, and changes in these participation times over two years were categorized into four groups(Consistently Inactive, Formerly Active, Newly Active, and Consistently Active). Dyslipidemia was classified according to the National Cholesterol Education Program Adult Treatment Panel III criteria. Multiple logistic regression analysis was used to calculate odds ratios (OR) and 95% confidence intervals (CI) to assess the association between changes in physical activity participation times and dyslipidemia. The analysis revealed that, when adjusting for sex and age, the Consistently Active group had a 40% lower odds ratio (OR=0.60, 95% CI=0.45, 0.81) of dyslipidemia compared to the Consistently Inactive group. Similar results were observed after adjusting for various confounding factors. Also, being newly active(OR=0.75, 95% CI=0.58, 0.97) or consistently active(OR=0.63, 95% CI=0.41, 0.97) in moderate-intensity physical activity, as well as being consistently active(OR=0.76, 95% CI=0.61, 0.95), in walking, independently reduced the risk of dyslipidemia after adjusting for various confounding variables. ConclusionsMaintaining a high level of physical activity was associated with a reduced risk of dyslipidemia. Therefore, national recommendations should focus on sustaining and increasing physical activity levels to manage dyslipidemia effectively.

Periodontal Disease and Metabolic Syndrome in Women at Prior High Risk for Gestational Diabetes.

This study aimed to assess the association between periodontal disease and metabolic syndrome (MetS) among women at prior high risk for gestational diabetes with the hypothesis that women with MetS show more signs of periodontal disease than women without MetS. A total of 112 women from an original study cohort of 348 women at high risk of gestational diabetes were examined 4-6 years postpartum. Diagnosis of MetS was based on the National Cholesterol Education Program Adult Treatment Panel III diagnostic criteria. Insulin resistance was approximated by the homeostatic model assessment for insulin resistance. Full-mouth examinations and panoramic radiographs provided the total dental index, number of teeth, and decayed, missing, and filled teeth index. Clinical examination assessed bleeding on probing, probing depth, visible plaque index, signs of infection, and clinical attachment levels. The periodontal inflammatory burden index (PIBI) was also calculated. Information on oral health habits, symptoms, and individual opinions on oral health was collected through questionnaires. Five years after delivery, 21% of the women had MetS, and they had more gingivitis compared to those without MetS (bleeding on probing: 52% and 44%, p = 0.011). Women with MetS tended to have more periodontitis than those without (39% and 25%, p = 0.13). A high PIBI correlated with insulin resistance (partial correlation of PIBI and homeostatic model assessment for insulin resistance: 0.25 p < 0.05). Periodontal disease was associated with insulin resistance and MetS in women at prior high risk of developing gestational diabetes.

Associations between Metabolic Syndrome, Grip Strength, and Depressive Symptom among Community-Dwelling Older Adult: A Cross-Sectional Study

PURPOSE: This study aimed to investigate the influence of muscle strength on the association between metabolic syndrome and depressive symptoms in community-dwelling older adults.METHODS: A cross-sectional survey was conducted on 630 randomly selected community-dwelling older adults aged 65 years and older living in Suwon City. After excluding those younger than 65 years and those with mobility limitations or musculoskeletal disorders, 619 participants were included in the final analysis. The 15-item Center for Epidemiologic Studies Depression Scale was used to assess depressive symptoms. Metabolic syndrome (MetS) was defined based on the National Cholesterol Education Program Adults Treatment Panel III criteria, which included triglyceride (TG), reduced blood high-density lipoprotein (HDL), high blood pressure (BP), elevated fasting plasma glucose, and waist circumference (WC). A digital dynamometer was used to assess grip strength, and the maximum value was determined.RESULTS: Depressive symptoms were significantly associated with relative hand grip strength (RHGS). Specifically, when comparing groups based on the presence of MetS and RHGS levels, grip strength (RHGS) was confirmed to have an important mediating effect on depressive disorders. The following odds ratios (OR) were observed: normal RHGS with metabolic syndrome (OR: 1.859, 95% CI: 0.867-3.985, &lt;i&gt;p&lt;/i&gt;=.111), low RHGS without metabolic syndrome (OR: 3.613, 95% CI: 1.735-6.522, &lt;i&gt;p&lt;/i&gt;&lt;.001), and low RHGS with MetS (OR: 4.145, 95% CI: 1.687-10.188, &lt;i&gt;p&lt;/i&gt;=.002).CONCLUSIONS: Depression appears to have a strong correlation with MetS in adults aged 65 and older. Among the various factors associated with MetS, muscle strength has the closest and most significant association with depressive symptoms. Therefore, implementing strategies to improve muscle strength may be crucial in reducing the likelihood of depression in the elderly population.

Metabolic syndrome among patients with type 2 diabetes in Jordan: A cross-sectional study.

Metabolic syndrome is a major public health problem worldwide and an independent predictor of cardiovascular disease in patients with type 2 diabetes (T2DM). This study aimed to determine the prevalence of metabolic syndrome and its individual components among Jordanian patients with T2DM. A cross-sectional design was conducted among T2DM patients at the National Center for Diabetes, Endocrinology and Genetics in Jordan. Data were collected using a structured questionnaire and clinical data extracted from medical records. The National Cholesterol Education Program-Adult Treatment Panel III (ATP III) and International Diabetes Federation (IDF) diagnostic criteria were used to define metabolic syndrome. Among 1017 participants aged between 22 and 90 years, the overall prevalence of IDF defined metabolic syndrome was 84.2% (72.5% and 96.2% among males and females, respectively). Using ATP III criteria, overall prevalence was 79.1% (77.4% and 80.8% among males and females, respectively). Advancing age, female gender, nonadherence to a diet regimen, sedentary lifestyle or insufficient physical activity, and duration of diabetes ≥10 years were significantly associated with increased odds of metabolic syndrome, regardless of the definition used. Current smoking status and family history of cardiovascular diseases were significantly associated with increased likelihood of ATP III defined metabolic syndrome. The prevalence of metabolic syndrome among Jordanian patients with T2DM is extremely high. The main modifiable risk factors of metabolic syndrome among these patients include nonadherence to a diet regimen, insufficient physical activity, being overweight/obese and smoking. It is recommended that healthcare providers counsel patients on the importance of maintaining physical activity, smoking cessation, and adherence to a diet regimen.

Systemic immune-inflammation mediates the association between Klotho protein and metabolic syndrome: findings from a large-scale population-based study.

This study utilized large-scale population data from the National Health and Nutrition Examination Survey (NHANES) to elucidate the relationship between the Klotho protein and metabolic syndrome along with its components. We further investigated the possible mediating effect of inflammation on these relationships. Our objective was to identify biomarkers for risk stratification and potential therapeutic targets for metabolic syndrome. This study enrolled 13,119 participants aged 40-79 years, spanning five NHANES cycles from 2007 to 2016, with complete information on metabolic syndrome and the Klotho protein. The definition of metabolic syndrome followed the criteria of the National Cholesterol Education Program-Adult Treatment Panel III. Survey-weighted logistic regression and subgroup analysis were used to explore the associations between serum Klotho protein levels and metabolic syndrome, along with its components. Mediation analysis was performed to investigate the mediating effects of inflammation-related markers, including white blood cells, neutrophils, lymphocytes, monocytes, the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), the systemic immune-inflammation index (SII) and the monocyte-to-HDL ratio (MHR), with the aim of elucidating how the Klotho protein influences the onset and progression of metabolic syndrome. The study participants had an average age of 56.06 years (95% CI: 55.76-56.37), with a Klotho protein concentration of 798.10 pg/ml (95% CI: 656.50-980.50) and a 43.77% prevalence of metabolic syndrome (n = 5742). In the crude model, Klotho was negatively correlated with metabolic syndrome and its components, including central obesity, hypertension, and hypertriglyceridemia. After adjusting for all confounding factors, Klotho was demonstrated to be negatively associated only with metabolic syndrome (OR: 0.82, 95% CI: 0.70-0.97), hypertension (OR: 0.83, 95% CI: 0.70-0.98), and hypertriglyceridemia (OR: 0.78, 95% CI: 0.67-0.91). Subgroup and interaction analyses revealed significant interactions between age, sex, race/ethnicity, body mass index, and Klotho. Additionally, mediation analysis demonstrated that leukocytes, neutrophils and monocytes accounted for 34.78%, 31.91% and 7.13%, respectively, of the associations between Klotho and metabolic syndrome. The serum concentration of Klotho protein was negatively associated with metabolic syndrome, with the relationship being partly mediated by systemic immune inflammation. The findings of this research revealed that the Klotho protein may be a valuable biomarker for risk stratification and a potential therapeutic target for metabolic syndrome.

Red cell distribution width/albumin ratio as a marker for metabolic syndrome: findings from a cross-sectional study

BackgroundMetabolic syndrome (MetS) imposes a significant health burden on patients globally. Chronic low-grade inflammation is pivotal in the onset and progression of this condition. However, the role of the novel inflammatory marker, red cell distribution width to albumin ratio (RAR), in the development of MetS remains unclear.MethodsThis population-based cross-sectional study utilized data from the 2011–2020 National Health and Nutrition Examination Survey (NHANES). Participants included individuals over 18 years old with complete data on serum albumin concentration, red cell distribution, and MetS and its components. MetS was defined using the criteria established by the National Cholesterol Education Program Adult Treatment Panel III. The calculation formula for RAR is: RAR = Red cell distribution width (%)/serum albumin (g/dL). Study participants were stratified into four quartiles based on RAR levels. Logistic regression analysis and subgroup analysis were employed to explore the independent interaction between RAR and MetS, as well as investigate the relationship between RAR levels and the specific components of MetS. Finally, the receiver operating characteristic (ROC) curve was used to assess the predictive efficacy of RAR for MetS.ResultsA total of 4899 participants were included in this study, comprising 2450 males and 2449 females; 1715 individuals (35.01%) were diagnosed with MetS. As the quartile of RAR increased, the proportion of individuals with MetS also increased. Spearman correlation analysis indicated a positive correlation between RAR and the insulin resistance index HOMA-IR. Logistic regression analysis, adjusting for multiple confounding factors, showed that each standard deviation increase in RAR was associated with a significant 1.665-fold increase (95% CI, 1.404–1.975; P < 0.001) in the odds of MetS prevalence. In logistic regression analysis stratified by quartiles of RAR, the risks of MetS in Q1-Q4 were 1.372 (95% CI, 1.105–1.704; P = 0.004), 1.783 (95% CI, 1.434–2.216; P < 0.001), and 2.173 (95% CI, 1.729–2.732; P < 0.001), respectively. Subgroup analyses and interaction tests demonstrated that gender, age, race, education, smoking status, and physical activity modified the positive association between RAR and MetS (p for interaction < 0.05). Additionally, analysis of the area under the receiver operating characteristic (ROC) curve showed that the optimal cutoff value for predicting MetS using RAR was 3.1348 (sensitivity: 59.9%; specificity: 60.6%; and AUC: 0.628).ConclusionsIncreasing RAR levels are associated with a higher risk of MetS. Therefore, greater attention should be given to patients with high RAR levels for improved prevention and treatment of MetS.

Associations of sarcopenia, obesity, and metabolic health with the risk of urinary incontinence in U.S. adult women: a population-based cross-sectional study.

Urinary incontinence (UI) significantly impairs women's quality of life. Identifying its risk factors is essential for developing effective interventions. Sarcopenia, characterized by the accelerated loss of muscle mass and function, is an emerging concern often linked to obesity and abnormal metabolic status, exacerbating various adverse health outcomes. This population-based study aimed to explore the independent and joint associations of sarcopenia, obesity, and metabolic health with UI risk, as well as to evaluate the mediating role of metabolic indicators in these associations. A total of 3,557 women aged ≥20 years from the National Health and Nutrition Examination Survey were included. Sarcopenia was assessed using the appendicular lean mass index (ALMI), and obesity was defined by body mass index and waist circumference. Metabolic health was evaluated using revised criteria from the National Cholesterol Education Program-Adult Treatment Panel III. UI was identified through responses to the "Kidney Conditions-Urology" questionnaire and classified into stress UI (SUI), urgency UI (UUI), and mixed UI (MUI). Multivariable logistic regression and restricted cubic spline models were used to evaluate the associations and visualize the relationship between ALMI and UI. Mediation models were constructed to assess the mediating role of metabolic indicators. We found that sarcopenia was significantly associated with an increased risk of MUI in the general population. Age-specific analysis revealed that sarcopenia is an independent risk factor for SUI in women aged ≥60, and for MUI in women aged 40-59 years. Sarcopenic obesity, particularly under central obesity criteria, further elevated the risk of UI. Notably, women with the metabolically unhealthy obese phenotype with sarcopenia were at the highest risk for both SUI and MUI. Metabolically unhealthy status, glycohemoglobin, vitamin D, and serum albumin levels were partial mediators of these associations. Our findings elucidated the complex interactions between sarcopenia, obesity, and metabolic health, underscoring the critical need for integrated therapeutic strategies that address both metabolic health and targeted nutritional interventions, aiming to enhance muscular health and effectively manage and prevent UI.

Associations of metabolic heterogeneity of obesity with the risk of dementia in middle-aged adults: three prospective studies

BackgroundThe associations of different obesity and metabolic phenotypes during midlife with the risk of incident dementia remain unclear. This study aimed to investigate the associations between metabolic heterogeneity of obesity and long-term risk of dementia.MethodsWe conducted prospective analyses from three cohorts, including the UK Biobank (UKB), Atherosclerosis Risk in Communities (ARIC) study, and Framingham Offspring Study (FOS). Eligible participants were those aged 45–65 years with valid assessments of body mass index (BMI) and metabolic status at the study baseline. Obesity was defined as a BMI of ≥ 30.0 kg/m2, while metabolic abnormality was defined as meeting ≥ 2 of the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) criteria. Metabolic heterogeneity of obesity was evaluated based on obesity and metabolic phenotypes and grouped as metabolically normal non-obesity (MNNO), metabolically abnormal non-obesity (MANO), metabolically normal obesity (MNO), and metabolically abnormal obesity (MAO).ResultsIncluded in this study were 295,823 participants aged 56.3 ± 5.9 years from the UKB, 12,547 participants aged 54.0 ± 5.7 years from the ARIC, and 2,004 participants aged 53.9 ± 5.9 years from the FOS. Over 4,348,208 person-years, a total of 6,190 participants (3,601 in the UKB, 2,405 in the ARIC, and 184 in the FOS) developed incident dementia. In the pooled analysis of three cohorts, metabolic abnormality was associated with a hazard ratio (HR) of 1.41 (95% confidence interval [CI]: 1.10–1.80) for dementia, while obesity was associated with an HR of 1.20 (1.03–1.41). Compared with MNNO, individuals with MANO and MAO had increased risks of dementia (pooled HR: 1.33, 95% CI: 1.04–1.71 for MANO and 1.48, 1.16–1.89 for MAO). However, there was no significant difference in the risk of dementia among MNO (pooled HR: 1.10, 95% CI: 0.98–1.24). In addition, participants who recovered from MANO to MNNO had a lower risk of dementia (pooled HR: 0.79, 95% CI: 0.64–0.97), as compared with stable MANO.ConclusionsMetabolic abnormality has a stronger association with dementia than obesity. Metabolically abnormal non-obesity and obesity, but not metabolically normal obesity, are associated with higher risks of incident dementia as compared with metabolically normal non-obesity. Recovering from an abnormal metabolic status to normal reduces the risk of dementia in populations without obesity. Our findings highlight the important role of metabolic status in the development of dementia and recommend the stratified management of obesity based on metabolic status.

Vitality and metabolic responses to integrated naturopathy and yogic interventions among metabolic syndrome – A protocol for randomized controlled trial

BackgroundMetabolic Syndrome (MetS) refers to a collection of interrelated physiological, biochemical, clinical, and metabolic variables that significantly raise the risk of type 2 diabetes, cardiovascular disease, and all-cause mortality. This trial aims to assess the effect of Naturopathy and Yogic Interventions on Vitality and Metabolic responses among patients with MetS. MethodThis trial is a single Centre Randomized Controlled Trial (RCT) and will be conducted at Nature Cure and Yoga Centre in the Southern part of India. Enrolled subjects with MetS, who fulfilled National Cholesterol Education Program Adult Treatment Panel III [NCEP ATP III Criteria], will be randomly allocated at a 1:1 ratio into Intervention and control groups. The Intervention group will receive Intensive Naturopathy and Yoga Intervention whereas the control group will receive a lifestyle advice during the initial consultation. The primary outcome will be measured by Heart Rate Variability (HRV), Blood Pressure Measurement, Biochemical Analysis, Anthropometric Measurement, Vitality Questionnaire, and Framingham Risk Score (FRS) which will be performed at the baseline and after 10 days of intervention and follow up will be taken at the 60th day. DiscussionA larger clinical trial will be possible as a result of this study's contribution to the understanding of the effectiveness of Yogic Interventions and Integrated Naturopathy for MetS and associated risk factors.

Muscle strength as a marker of metabolic health in kidney transplant recipients: A cross-sectional study

BackgroundMuscle strength is often used as an indirect indicator of metabolic health across different age groups in healthy individuals. However, in kidney transplant recipients, this measure may be less accurate due to metabolic changes induced by immunosuppressive medications. AimTo compare muscle strength between kidney transplant recipients with metabolic syndrome (MS) and those without this condition. MethodsA cross-sectional analytical study was conducted with 29 participants (22 men and seven women) aged 18–50 years, having undergone a kidney transplant for over a year and without experiencing graft failure. To determine the presence of MS, the criteria proposed by the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP-III) was used. Biochemical markers (triglyceride, total cholesterol, HDL, LDL, and glucose levels) were evaluated through a capillary sample. Muscle strength was assessed through three tests: long jump, elbow flexion, and grip strength. ResultsThe mean age was 36 ± 11.3 years, and the average transplant time was 4.5 ± 2.8 years. The prevalence of MS was 58.6%. Transplant recipients with MS performed less in all tests assessing muscle strength than those without this condition (p < 0.001∗). ConclusionsThe main finding of this research is that kidney transplant patients with MS performed worse in muscle strength tests compared to those without the condition.

.

Background: Dyslipidaemia has been proposed as a potential risk factor for breast cancer. This study aimed to evaluate the association between serum lipid profiles and breast cancer among women, comparing lipid levels between breast cancer patients and healthy controls. Methods: A hospital-based cross-sectional observational study was conducted at SMS Medical College and Hospital, Jaipur, from ethics committee approval until June 2024. The study included 100 breast cancer patients and 100 matched healthy controls. Inclusion criteria were individuals aged 18 years or older with informed consent, while exclusion criteria included critically ill patients, those with malignancies other than breast cancer, and those on lipid-lowering therapy. The lipid profile was assessed according to the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines. Data collection involved clinical examination, anthropometric measurements, and biochemical analysis of serum lipid levels. Results: The mean age of participants was 48.5 years for the Case Group and 45.92 years for the Control Group. Serum lipid profiles showed significantly higher levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL), and triglycerides (TG) in breast cancer patients compared to controls, with TC at 197 ± 42.2 mg/dl vs. 174.06 ± 38.46 mg/dl, LDL at 152.65 ± 32.57 mg/dl vs. 121.09 ± 24.56 mg/dl, and TG at 162.12 ± 15.64 mg/dl vs. 138.23 ± 22.99 mg/dl. High-density lipoprotein cholesterol (HDL) was significantly lower in breast cancer patients (36.0 ± 16.60 mg/dl vs. 50.60 ± 17.64 mg/dl). Subgroup analysis by age showed similar trends across different age groups. No significant differences were observed between premenopausal and postmenopausal women in lipid levels. Conclusion: Elevated serum lipid levels, particularly TC, LDL, and TG, are associated with breast cancer. Monitoring and managing lipid levels may offer potential benefits in breast cancer prevention and treatment strategies.

Gender difference in metabolic syndrome and some associated factors among the elderly at Thai Binh Medical University Hospital

Background: The prevalence of metabolic syndrome (MetS) in adults in Thai Binh province was still high (28.4%). However, previous studies on the prevalence of MetS among the elderly were still limited and inconsistent. Therefore, The objective of this study was to examine gender differences in metabolic syndrome (MetS) characteristics and some associated factors. Materials and Methods: A convenience sample of 404 elderly outpatients was recruited from Thai Binh Medical University Hospital. The general information and history of falls, sleep quality score, smoking, alcohol use, and body mass index (BMI) of the subjects were collected through questionnaires, and each patient's height, Weight, waist circumference (WC), and other physical signs were measured. MetS was diagnosed based on the criteria of the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III). Logistic regression analysis was used to analyze the risk factors of MetS and its components. Results: The prevalence of MetS in elderly females (36.0%) is higher than in males (18.5%) (p&lt;0.001). The three component indices of MetS are low HDL-cholesterol ratio, high triglyceride (TG), and higher WC in females than males. In contrast, the two indices, high blood pressure (BP) and elevated blood sugar (BS), showed the opposite. Some factors associated with MetS in both genders are BMI, BS, and TG, but older men with a history of smoking [OR (95%CI), 3.2 (1.2-8.2)], and older women with a history of falls [OR (95%CI), 1.6 (1.1-2.4)] have a higher risk of MetS than other subjects. Conclusions: There were significant differences in MetS components in the two sexes. In additions, there are different factors related to the prevalence of MetS in both sexes: smoking history in men and history of falls in women. Keywords: Gender differences; Metabolic syndrome; Elderly; Risk factors.

Association between Metabolic Syndrome and the Severity of Ischemic Heart Disease

Ischemic Heart Disease (IHD) was a leading cause of mortality worldwide, often complicated by metabolic syndrome, which includes hypertension, hyperglycemia, and dyslipidemia. Objective: To investigate the association between metabolic syndrome and the severity of ischemic heart disease. Methods: Data were collected from the cohort’s existing records, including clinical assessments, laboratory tests, and self-reported questionnaires. Metabolic syndrome components were evaluated using the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria. Participants were classified as having metabolic syndrome if they met three or more of the following criteria: abdominal obesity, elevated blood pressure, elevated fasting glucose, high triglycerides, and low HDL cholesterol. IHD incidence was determined through medical records, hospital admissions, and mortality data, defined as non-fatal myocardial infarction, unstable angina, or coronary revascularization. Statistical analysis included calculating the incidence rate of IHD for participants with and without metabolic syndrome, expressed as IHD cases per 1,000 person-years. Cox proportional hazards regression models were used to assess the association between metabolic syndrome and IHD incidence, adjusting for confounders such as age, sex, smoking status, physical activity, and family history of cardiovascular disease. Hazard Ratios (HRs) with 95% Confidence Intervals (CIs) were reported. Results: The incidence of IHD was significantly higher in participants with metabolic syndrome. Cox regression showed metabolic syndrome was associated with increased IHD incidence (HR: 2.70, 95% CI: 1.50–4.80, p &lt; 0.001). Conclusion: Metabolic syndrome was significantly associated with IHD incidence. Early identification and management were essential to reduce IHD risk.

Associations between body fat anthropometric indices and mortality among individuals with metabolic syndrome

BackgroundThe distribution of body fat and metabolic health may contribute to the onset of metabolic syndrome (MetS), but the associations between body fat anthropometric indices (AIs) and mortality in individuals with MetS remain unclear.MethodsParticipants aged 18 years or older with MetS were recruited from the NHANES 1999–2018. The body fat anthropometric indices included the a body shape index (ABSI), body roundness index (BRI), cardiometabolic index (CMI), visceral adiposity index (VAI), waist triglyceride index (WTI), lipid accumulation product (LAP), atherogenic index of plasma (AIP), and triglyceride‒glucose (TyG) index. MetS was defined according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) criteria. Mortality data were obtained from the National Death Index through December 31, 2019.ResultsData were collected from 8,379 individuals with MetS, with a median follow-up of 8.5 years, of whom 1,698 died from all causes and 568 from the CCD. The random survival forest (RSF) analysis indicated that the ABSI had the strongest predictive power for both all-cause mortality and CCD mortality among the eight body fat AIs. After adjusting for multiple variables, the ABSI was found to be linearly and positively associated with all-cause and CCD mortality in individuals with MetS. Participants in the highest quartile of ABSI had an increased risk of all-cause (HR = 1.773 [1.419–2.215]) and CCD (HR = 1.735 [1.267–2.375]) mortality compared with those in the lowest quartile. Furthermore, the ABSI predicted areas under the curve (AUCs) of 0.735, 0.723, 0.718, and 0.725 for all-cause mortality at 3, 5, 10, and 15 years, respectively, and 0.774, 0.758, 0.725, and 0.715 for CCD mortality, respectively.ConclusionAmong eight body fat AIs, the ABSI exhibited the strongest predictive power for mortality in individuals with MetS. Higher ABSI values significantly increased all-cause mortality and CCD mortality in participants with MetS.